Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516434 | 1.00 | KMT2A (0.75) | KMT2AEPHX2HDAC3HDAC4HDAC1 | |
| SCHEMBL29669240 | 0.95 | KMT2A (0.70) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL793384 | 0.93 | KMT2A (0.85) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL4673462 | 0.93 | KMT2A (0.73) | KMT2AEPHX2HDAC3HDAC4HDAC1 | |
| SCHEMBL30204049 | 0.89 | KMT2A (0.66) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL1157227 | 0.89 | KMT2A (0.66) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29458423 | 0.88 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL29401182 | 0.88 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL887559 | 0.88 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL6889085 | 0.88 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796003-B1 | Label free kinase assays and reagents | PLEXERA, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-7919653-B2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| EP-2157429-A2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | Reverse Proteomics Research Institute Co., Ltd (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-7504709-B2 | Electronic device, method of manufacturing an electronic device, and electronic apparatus | SEIKO EPSON CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20080176341-A1 | Method for Suppressing Intermolecular Nonspecific Interaction and for Intensifying Intermolecular Specific Interaction on Metal Surface | REVERSE PROTEMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1553412-A1 | METHOD OF INHIBITING NONSPECIFIC INTERACTION BETWEEN MOLECULES ON SOLID PHASE SUPPORT | Reverse Proteomics Research Institute Co., Ltd (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | CD2BP2, CD14, SPR | KMT2A 3769/4885EPHX2 2680/4885HDAC3 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.